René Roy (chemist)

From Wikipedia, the free encyclopedia
René Roy
Born (1952-11-04) November 4, 1952 (age 71)
Sherbrooke, Quebec
NationalityCanadian
Alma materUniversité de Montréal
Known forSemi-synthetic glycoconjugate vaccines
AwardsCanada Research Chair in Medicinal Chemistry (2004-2017)
Gold Medal from the World Intellectual Property Organization (2005)
Tech Museum Award-Technology Benefiting Humanity (2005)
Scientific career
FieldsMedicinal chemistry
InstitutionsUniversité du Québec à Montréal
University of Ottawa
Université de Montréal
Doctoral advisorStephen Hanessian

René Roy (born November 4, 1952) is a Canadian organic chemist from Quebec, specializing in glycobiology and carbohydrate chemistry. He is professor emeritus,[1] Department of chemistry, at the Université du Québec à Montréal (UQAM)[2] and associate professor at the Institut National de la Recherche Scientifique (INRS) – Institut Armand-Frappier (IAF). He is the founder and former director of PharmaQAM,[3] a biopharmaceutical research center based at UQAM, focusing on the discovery of new bioactive molecules, their mechanism of action and the vectorization of drugs. He is a pioneer in the development of synthetic glycoconjugate vaccines both for human and veterinary health, having co-developed the first and sole marketed semi-synthetic vaccine for human use,[4] preventing bacterial meningitis and pneumonia in developing countries.[5][6]

Education[edit]

René Roy completed his Ph.D. in carbohydrate chemistry from Université de Montréal in 1980,[7] with Stephen Hanessian,[8] developing synthetic methodologies and the syntheses of natural compounds using carbohydrate precursors (Chiron approach).

Career[edit]

Immediately after his Ph.D, in 1980, René Roy joined the National Research Council (NRC) in Ottawa where he worked as researcher in the Institute for Biological Sciences. Then, in 1985, he began his career as professor in the department of chemistry of the University of Ottawa where he served until December 2002. In parallel, he held the positions of Associate Director of the Ottawa-Carleton Chemistry Institute from 1993 to 1996, Director from 1996 to 1999, and again Associate Director in 2000. From 2002 to 2004, he was chairman of the American Chemical Society (ACS) Division of Carbohydrate Chemistry and, in 2005, head of the ACS awards committee.[9]

In 2008, he returned to Montreal to teach organic chemistry at the Université du Québec à Montréal. There, he also founded the PharmaQAM biopharmaceutical research center which gathers some 50 professors and 17 institutions with common interests in the molecular aspects of medicinal chemistry and drug discovery[10] working on new bioactive molecules, their mechanism of action and the way they are vectorized in vivo.[9] He served as director of PharmaQAM until December 2017.

During his career, René Roy has co-developed meningitis vaccines, for humans[6][11][5] and animals,[12] that led to commercial success. One of them, targeting the Haemophilus influenzae b (HIB) bacteria, has been designed jointly with the Cuban researcher Vincente Verez Bencomo to prevent lethal meningitis and pneumonia in developing countries. It is the first human semi-synthetic glycoconjugate vaccine approved and remains the only one. In use since 2004, more than 34 million doses[4] have been distributed to children in several countries including Vietnam, Syria, Brazil, Venezuela and Angola, eradicating the infectious disease in Cuba.[11] Rene Roy is a cofounder of Glycovax Pharma,[13] a biotech company operating in Montreal, developing glycochemistry-based treatments against cancer and other disease with unmet medical needs.

Research[edit]

Research interests[edit]

René Roy uses carbohydrate chemistry to develop neoglycoconjugates and polymers to treat disease related to glycoproteins such as bacterial infections and cancers. His synthesis of new glycan structures,[14] among which glycopolymers, glycodendrimers, and glycodendrimersomes (terms that he first developed) enabled progress in the area of multivalent molecular recognition mechanisms. He is known for his work on semi-synthetic glycoconjugate vaccines.[6] He has designed a breast cancer vaccine prototype.[15][16]

René Roy has authored more than 370 scientific articles and 2 books on vaccines and glycomimetics.[17] He has 5 patents[18] to his credit, of which two ended in commercial products[6]

Honors and awards[edit]

See also[edit]

References[edit]

  1. ^ "UQAM official website - Professeurs Émérites (in French)". Archived from the original on 2019-04-19. Retrieved 2019-01-23.
  2. ^ a b "UQAM official website - Répertoire des Professeurs - Rene Roy (in French)".
  3. ^ "PharmaQAM website - Direction". Archived from the original on 2019-01-23. Retrieved 2019-01-23.
  4. ^ a b Adamo, Roberto (2017). "Advancing Homogeneous Antimicrobial Glycoconjugate Vaccines". Accounts of Chemical Research. 50 (5): 1270–1279. doi:10.1021/acs.accounts.7b00106. PMID 28463499. {{cite journal}}: Unknown parameter |agency= ignored (help)
  5. ^ a b Ottawa, University. "A vaccine that pays big".
  6. ^ a b c d Angiolini, Daphné. "Chimie - Un vaccin " cubain " (in French)". Le Devoir. Retrieved November 26, 2005.
  7. ^ "Glyconet – Rene Roy's description".
  8. ^ Roy, René; Shiao, Tze Chieh; Rittenhouse-Olson, Kate (2013). "Glycodendrimers : versatile tools for nanotechnology". Brazilian Journal of Pharmaceutical Sciences. 49: 85–108. doi:10.1590/S1984-82502013000700008. S2CID 33532339. {{cite journal}}: Unknown parameter |agency= ignored (help)
  9. ^ a b "Glycovax Pharma - Rene Roy's description".
  10. ^ "PharmaQAM website".
  11. ^ a b "Hib Vaccine Team". myhero.com.
  12. ^ "Combattre l'infection chez le porc (in French)". Actualités UQAM. Retrieved November 25, 2015.
  13. ^ "Glycovax Pharma Scientific Team".
  14. ^ "Rene Roy's publications". Google Scholar.
  15. ^ "Montréal Métro: excellence en recherche sur le cancer (in French)" (PDF). Montreal In Vivo. Retrieved January 23, 2019.
  16. ^ a b "Le professeur René Roy, lauréat du Prix de carrière scientifique (in French)". Actualités UQAM. Retrieved October 10, 2008.
  17. ^ "ResearchGate page Rene Roy". researchgate.net.
  18. ^ "Linkedin Profile Rene Roy – Patents list".
  19. ^ a b c "Biographical Notes Rene Roy". NanoPDF. Retrieved May 5, 2018.
  20. ^ a b c "UQAM official website – Pr Rene Roy". x.
  21. ^ "Ottawa University website – Rene Roy's card".
  22. ^ Roy, Rene; Vidal, Sebastien (23 April 2015). "from Rene Roy's biography in the book Carbohydrate Chemistry: Proven Synthetic Methods, Volume 3". CRC Press. Google books. ISBN 9781466583580.
  23. ^ "Prix et Médaille d'or, page 2 (in French)" (PDF). Journal UQAM. Retrieved September 6, 2005.
  24. ^ "Section 2010-2001 Laureates, year 2005, see "Hib Vaccine Team - Cuba"". thetech.org. Archived from the original on 2021-02-03. Retrieved 2019-01-23.
  25. ^ "Southern Illinois University - The Probst Lecture Series".
  26. ^ "Foundation of Stars" (PDF). foundationofstars.ca.
  27. ^ "En bref - Cinq doctorats honoris causa à l'UQAM (in French)". Le Devoir. Retrieved June 12, 2009.
  28. ^ "Le professeur René Roy reçoit la Médaille de l'UQAM (in French)". Actualités UQAM. Retrieved June 15, 2009.
  29. ^ "Prix Acfas Léo-Pariseau" (in French). Association francophone pour le savoir. Retrieved 25 January 2019.
  30. ^ "Le professeur René Roy est nommé membre du Cercle d'excellence de l'Université du Québec (in French)". Actualités UQAM. Retrieved August 31, 2011.

External links[edit]

Retrieved from "https://en.wikipedia.org/w/index.php?title=René_Roy_(chemist)&oldid=1189343730"